FDA nod for Gilead to expand hepatitis drug to six years or older patients
HQ Team March 28, 2024: US regulator, the FDA has approved Gilead Sciences, Inc.’s supplemental new drug application for treating chronic hepatitis B.
Drugs
Health
Pharma